Luphere Depot

Luphere Depot
Product Description

Luphere Depot (Leuprorelin) is a generic specialty drug of Lupron/Leuplin. Luphere Depot is a marketed product in Korea since January 2005. Currently, Luphere Depot is under development for US and Japan.

 

Key Features:

1) Mode of action: GnRH Agonist

2) Indication: Prostate cancer, Endometriosis,  Uterine Fibroid, Postmenopausal Breast Cancer, Central Precocious Puberty

3) Development Status: 1, 3 & 4 month for US; 1 & 3 months for Japan research completed. 

4) Sustained-release depot: PLGA polymer encapsulated formulation; Equivalent PD profile to the reference drug; and manufactured in cGMP level facility

 

We are actively seeking an overseas partner who is interested to run clinical development (bioequivalence studies), registering and commercializing the Luphere Depot outside Korea.

Read more Show less

Daewoong Pharmaceutical Co.,Ltd

  • KR
  • 2015
    On CPHI since
  • 1000 - 4999
    Employees
Company types
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Out-licensing specialist
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
View company profile
Categories
more categories Show less
Specifications
  • Supplied from
    Korea, Democratic People's Republic of
More specifications Fewer specifications
Sales Markets
Show more Show less

Daewoong Pharmaceutical Co.,Ltd

  • KR
  • 2015
    On CPHI since
  • 1000 - 4999
    Employees
Company types
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Out-licensing specialist
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
View company profile

More Products from Daewoong Pharmaceutical Co.,Ltd (8)

  • DWRX1010 (Colonoscopy Bowel Preparation Drug)

    Product DWRX1010 (Colonoscopy Bowel Preparation Drug)

    ※ DWRXs Differentiation Points 1) Maximize compliance in the form of minitablets. 2) Containing simethicone to remove foam in the colon, enabling smooth colonoscopy. 3) Maximizes the convenience of taking medication, and low water intake. ※Development Strategy 1) Non-clinical trial (KR) and patent applica...
  • NABOTA®

    Product NABOTA®

    Botulinum toxin type A  
    Indication: Glabella Lines (Approved in KR, US, CA, EU), Post Stroke Upper Limb Spasticity, Crow's feet, Blepharospasm, Benign Masseteric Hypertrophy (Approved in KR)
    - Nabota is the only 900kDa Neurotoxin approved in the US and EU since Botox.- It has demonstra...
  • CLOPAM(Microneedle Patch)

    Product CLOPAM(Microneedle Patch)

    Microneedle is the most active and evolved form of transdermal drug delivery. Its formulation utilizes micro-sized (usually under 1mm in length) needles to deliver drugs past the stratum corneum. CLOPAM is Daewoong Therapeutics' exclusive and patented manufacturing technology that ensures efficient drug ...
  • ENVLO®

    Product ENVLO®

    Envlo (Enavogliflozin) is a best-in-class SGLT2 inhibitor for T2DM. 
    Highlights of Envlo are: 
    * Launched in Korea from May 2023
    * Approved by Korea MFDS in 2022 for T2DM 
    * T2DM Phase III was completed in Korea as a monotherapy and in combinations with other anti-diabetics (du...
  • FEXUCLUE®

    Product FEXUCLUE®

    Fexuclue (Fexuprazan) is the best-in-class novel anti acid secretion agent with rapid onset time and potent acid suppressive effect, addressing the growing unmet needs of PPIs

    Highlights of Fexuclue are: * Launched in Korea (2022) and Philippines (2023)
    * Approved in Chile and Ecuador qq...
  • Luphere Depot_3.75mg-Inj.

    Product Luphere Depot_3.75mg-Inj.

    Leuprorelin Acetate

    Indication: Prostate cancer, Endometriosis, Pre-menopausal breast cancer, Uterine leiomyomata (Fibroids), Central Precocious Puberty

    - Luphere has two formulations; Daewoong＊s proprietary patented spray-drying formulation and the emulsion formulation which will make...
  • Olostar 20/10mg and 40/20mg - Tab.

    Product Olostar 20/10mg and 40/20mg - Tab.

    Olmesartan medoxomil, Rosuvastatin

    Indication: Concomitant Hypertension and Dyslipidemia

    <World's 1st fixed dose combination of olmesartan and rosuvastatin>
    1. Developed with Daewoong's patented formulation technology
    2. Indicated for the treatment of both hypertensio...
  • URSA

    Product URSA

    25, 50, 100, 200, 250, 300mg - Tab., Soft Cap., Hard Cap.

    UDCA (Ursodeoxycholic Acid)

    Indication:
    Cholestasis(include PBC, PSC), Viral hepatitis C, Gallstone

    URSA improves liver function in chronic hepatitis patients, improves symptom and histopathology in Cholestatis...

Daewoong Pharmaceutical Co.,Ltd resources (1)